-
公开(公告)号：EP3621968A1
公开(公告)日：2020-03-18
申请号：EP18728518.4
申请日：2018-05-08
申请人： Astrazeneca AB
发明人： KETTLE, Jason, Grant , BAGAL, Sharanjeet, Kaur , BOYD, Scott , EATHERTON, Andrew, John , FILLERY, Shaun, Michael , ROBB, Graeme, Richard , RAUBO, Piotr, Antoni
IPC分类号： C07D498/14 , A61P35/00 , A61K31/519
-
公开(公告)号：EP3790884A1
公开(公告)日：2021-03-17
申请号：EP19723368.7
申请日：2019-05-07
申请人： Astrazeneca AB
发明人： KETTLE, Jason, Grant , BAGAL, Sharanjeet, Kaur , EATHERTON, Andrew, John , FILLERY, Shaun, Michael , ROBB, Graeme, Richard , LAMONT, Scott, Gibson , KEMMITT, Paul, David , GOLDBERG, Frederick, Woolf
IPC分类号： C07D498/14 , A61K31/55 , A61P35/00
-
公开(公告)号：EP3371183A1
公开(公告)日：2018-09-12
申请号：EP16790601.5
申请日：2016-11-02
申请人： Astrazeneca AB
发明人： PIKE, Kurt, Gordon , BARLAAM, Bernard, Christophe , HUNT, Thomas, Anthony , EATHERTON, Andrew, John
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
CPC分类号： A61K31/4745 , A61K31/282 , A61K31/407 , A61K31/704 , A61K33/24 , A61K45/06 , A61K2121/00 , A61K2300/00 , A61P35/00 , C07D471/04
摘要： The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where x, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
-
公开(公告)号：EP3350180B1
公开(公告)日：2020-11-11
申请号：EP16770461.8
申请日：2016-09-15
申请人： Astrazeneca AB
发明人： PIKE, Kurt, Gordon , BARLAAM, Bernard, Christophe , HUNT, Thomas, Anthony , EATHERTON, Andrew, John
IPC分类号： C07D471/04 , A61K31/4745 , A61P35/00
-
公开(公告)号：EP3370722A1
公开(公告)日：2018-09-12
申请号：EP16788723.1
申请日：2016-11-02
申请人： Astrazeneca AB
发明人： PIKE, Kurt, Gordon , BARLAAM, Bernard, Christophe , HUNT, Thomas, Anthony , EATHERTON, Andrew, John
IPC分类号： A61K31/444 , A61K31/4545 , A61P35/00 , C07D471/04
CPC分类号： A61K31/4745 , A61K31/17 , A61K31/192 , A61K31/195 , A61K31/407 , A61K31/4184 , A61K31/4741 , A61K31/506 , A61K31/555 , A61K31/675 , A61K31/704 , A61K33/24 , A61K39/39541 , A61K2300/00 , A61P35/04 , C07D471/04
摘要： and pharmaceutically acceptable salts thereof, where R1, R2, R3 and R4 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
-
公开(公告)号：EP3350180A1
公开(公告)日：2018-07-25
申请号：EP16770461.8
申请日：2016-09-15
申请人： Astrazeneca AB
发明人： PIKE, Kurt, Gordon , BARLAAM, Bernard, Christophe , HUNT, Thomas, Anthony , EATHERTON, Andrew, John
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
摘要： and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.016 秒)
